Study on an immunosensor based on gold nanoparticles and a nano-calcium carbonate/Prussian blue modified glassy carbon electrode

Disposable label-free electrochemical immunosensor based on prussian blue nanocubes for four breast cancer tumor markers

A compact and low-cost multi-electrode array (MEA) is presented, comprising four working electrodes with shared reference and auxiliary electrodes. Prussian blue was electrodeposited on the MEA using chronoamperometry with a positive potential of 0.3 V. Prussian blue nanocubes (PBNCs) were formed, which were observed using scanning electron microscopy. The precision of the four working electrodes was demonstrated using ferric/ferro cyanide (RSD <5.8%). The surface roughness of the working electrodes of the fabricated MEA was investigated by atomic force microscopy and compared with that of a commercial MEA. The PBNCs were the platform for a label-free immunosensor that detected four breast cancer tumor markers (CEA, CA125, CA153, and CA199) using specific antibodies. The processes of antibody immobilization were investigated using cyclic voltammetry and electrochemical impedance spectroscopy. The immunosensor was evaluated using real human serum samples, yielding acceptable recoveries (95.1-104.1%, RSD < 3.9) for the four tumor markers. These findings confirmed that our label-free immunosensor based on PBNCs could be a promising device for point-of-care testing and could pave the way for the establishment of new platforms for the screening of various breast cancer tumor markers.

Facile Synthesis of a MoS2-Prussian Blue Nanocube Nanohybrid-Based Electrochemical Sensing Platform for Hydrogen Peroxide and Carcinoembryonic Antigen Detection

Herein, an electrochemical detection platform was designed based on a Prussian blue nanocube-decorated molybdenum disulfide (MoS₂-PBNCs) nanocomposite. Shape-controlled and high-dispersion PBNCs were supported on the MoS₂ nanosheet surface, which would be simply controlled by varying the experimental conditions. Expectedly, such obtained MoS₂-based nanocomposites possessed excellent electrocatalytic ability, which could be employed to construct an electrochemical sensor for nonenzymatic hydrogen peroxide (H₂O₂) detection. More interestingly, MoS₂-PBNCs nanocomposites could be utilized to construct a sensor for label-free detection of carcinoembryonic antigen (CEA). The electrochemical response of the MoS₂-based immunosensor was linear with the CEA concentration ranging from 0.005 to 10 ng mL^-1. Moreover, the detection limit was calculated to be 0.54 pg mL^-1. The acceptable selectivity and high stability made such immunosensors detect CEA in human serum with satisfactory results. All data indicated that this MoS₂-PBNCs nanocomposite may be a promising electrochemical sensing platform for the detection of chemical and biological molecules.

Perspectives and potential applications of nanomedicine in breast and prostate cancer

Nanomedicine is a branch of nanotechnology that includes the development of nanostructures and nanoanalytical systems for various medical applications. Among these applications, utilization of nanotechnology in oncology has captivated the attention of many research endeavors in recent years. The rapid development of nano-oncology raises new possibilities in cancer diagnosis and treatment. It also holds great promise for realization of point-of-care, theranostics, and personalized medicine. In this article, we review advances in nano-oncology, with an emphasis on breast and prostate cancer because these organs are amenable to the translation of nanomedicine from small animals to humans. As new drugs are developed, the incorporation of nanotechnology approaches into medicinal research becomes critical. Diverse aspects of nano-oncology are discussed, including nanocarriers, targeting strategies, nanodevices, as well as nanomedical diagnostics, therapeutics, and safety. The review concludes by identifying some limitations and future perspectives of nano-oncology in breast and prostate cancer management.